关注
Ravi Vyzasatya
Ravi Vyzasatya
Lonza Walkersville
在 lonza.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice
A Jain, HS Olsen, R Vyzasatya, E Burch, Y Sakoda, EY Mérigeon, L Cai, ...
Arthritis research & therapy 14, 1-12, 2012
672012
Evaluating the quality of a cell counting measurement process via a dilution series experimental design
S Sarkar, SP Lund, R Vyzasatya, P Vanguri, JT Elliott, AL Plant, ...
Cytotherapy 19 (12), 1509-1521, 2017
282017
Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer
A Jain, B Poonia, EC So, R Vyzasatya, EE Burch, HS Olsen, EY Mérigeon, ...
European journal of cancer 49 (15), 3344-3352, 2013
202013
The Cre-loxP recombination-based reporter system for plant transcriptional expression studies
T Shigaki, RR Vyzasatya, AB Sivitz, JM Ward, H Sze, KD Hirschi
Plant molecular biology 58, 65-73, 2005
112005
2014 TERMIS-AM ConferenceWashington, DCDecember 13–16, 2014
L Wong, D Glaser, Y Choi, J Pegan, A Engler, J Sim, B Pruitt, M Khine, ...
Tissue Engineering Part A 20 (S1), s-1-s-140, 2014
12014
Process Development and Manufacturing: BIOANALYTICAL CHALLENGES IN THE DEVELOPMENT AND VALIDATION OF BIOASSAYS USED IN CELL THERAPY
RJ Meesters, R Vyzasatya
Cytotherapy 25 (6), E10, 2023
2023
Experimental and statistical methods for quantifying and comparing the performance of cell enumeration techniques
S Sarkar, S Lund, R Vyzasatya, P Vanguri, M Halter, J Elliot, S Lin-Gibson, ...
Cytotherapy 17 (6), S27-S28, 2015
2015
Resistance of KRAS Mutant Colon Cancers to Cetuximab May Be Overcome Through Antibody Engineering
A Jain, B Poonia, WS Twadell, E So, R Vyzasatya, NN Hanna, ...
Journal of Surgical Research 172 (2), 203-204, 2012
2012
系统目前无法执行此操作,请稍后再试。
文章 1–8